Original Article

Place in Therapy for Liraglutide and Saxagliptin for Type 2 Diabetes

Authors: M. Shawn McFarland, PharmD, Meghan Brock, PharmD, Casey Ryals, PharmD

Abstract

Background: The release of incretin based therapeutic entities has brought the possibility to offer control of the disease by augmenting a natural process in the body that has become deficient with type 2 diabetes. Liraglutide, an incretin mimetic, and saxagliptin, a dipeptidyl peptidase-4 inhibitor, have been approved and introduced to the market.


Objectives: To (a) review the efficacy and safety data of for the treatment of type 2 diabetes, and (b) recommend their place in therapy.


Methods: A MEDLINE search was performed using key words "liraglutide" and "saxagliptin" for articles published and available through July 2010.


Results: The Liraglutide Effect and Action in Diabetes (LEAD) trials encompassed six published phase 3 trials that evaluated the efficacy and safety of liraglutide either as monotherapy or in addition to oral hypoglycemic medications. Saxagliptin has been studied as monotherapy and in combination to oral hypoglycemic medications.


Conclusions: Liraglutide has been shown to improve glucose control and weight loss compared to other pharmacologic treatments with diabetes and may offer improved control with a decrease in daily dosing compared to exenatide. Saxagliptin improved glucose control as monotherapy or in combination with medications other than sulfonylurea. Saxagliptin has not been evaluated head to head with sitagliptin other than in combination with metformin where saxagliptin was deemed noninferior. Given the lack of long-term safety and clinical data compared to current treatment modalities, and more importantly the overall cost of the therapies to the health care system, a global recommendation for their use cannot be issued.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Standards of medical care in diabetes-2010. Diabetes Care 2010;33(suppl):S11-S61. Available at: http://care.diabetesjournals.org/content/33/Supplement_1/S11.full.pdf+html. Accessed October 22, 2010.
 
2. Defronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787-835.
 
3. Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS-34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 2008;352:854-865.
 
4. Kahn S, Haffner S, Heis M, et al. Glycemic durability of rosiglitazone, metformin and or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.
 
5. Holman R, Paul S, Bethel MA, et al. 10-Year follow up of intensive control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
 
6. Nathan D, Buse J, Davidson B, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203.
 
7. Robarb HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologist medical guideline for clinical practice for the management of diabetes mellitus. Endocrine Practice2007;13:S1-S68.
 
8. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795.
 
9. Van De Koppel S, Choe HM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm 2008;14:363-380.
 
10. Salera M, Giacomoni P, Pironi L, et al. Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity. J Clin Endocrinol Metab 1982;55:329-336.
 
11. Baggio L, Druker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157.
 
12. Deacon CF, Nauck MA, Meier J, et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000;85:3575-3581.
 
13. Druker DJ. Glucagon-like peptide-1 and the Islet {beta}-cell: augmentation of cell proliferation and inhibition of apoptosis. Mol Endiocrinol 2003;17:161-171.
 
14. Bollag RJ, Zhong Q, Ding KH, et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol 2001;177:35-41.
 
15. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-613.
 
16. Meneilly GS, McIntosh CH, Pederson RA, et al. Glucagon-like peptide-1 (7-37) augments insulin release in elderly patients with diabetes. Diabetes Care 2001;24:964-965.
 
17. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel group study. Lancet 2002;359:824-830.
 
18. Todd JF, Edwards CM, Ghatei MA, et al. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clin Sci (Colch) 1998;95:325-329.
 
19. Victoza (Liraglutide Injection) [package insert]. Princeton, NJ, Novo Nordisk, 2010.
 
20. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab2008;93:3703-3716.
 
21. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulfonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Med2009;26:268-278.
 
22. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes (the LEAD-2 Study). Diabetes Care2009;32:84-90.
 
23. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481.
 
24. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met-TZD). Diabetes Care 2009;32:1224-1230.
 
25. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 Met+SU). Diabetologia 2009;52:2046-2055.
 
26. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
 
27. Buse JB, Sesti G, Schmidt W, et al. Switching once daily liraglutide from twice daily exenatide further improves glycemic control in patients with type 2 diabetes using oral medications. Diabetes Care2010;33:1300-1303.
 
28. Parks M, Rosenbaugh C. Weighing the risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-777.
 
29. Drucker DJ, Sherman SI, Gorelick FS, et al. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010;33:428-433.
 
30. Parola A. FDA Advisory Committee non-clinical briefing document. New drug application 2009;22-341.
 
31. Drab SR. Incretin-based therapies for type 2 diabetes mellitus. Pharmacotherapy 2010;30:609-624.
 
32. Onglyza [package insert]. Princeton, NJ, Bristol-Myers Squibb Company, 2009.
 
33. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-386.
 
34. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of sitagliptin monotherapy in treatment naïve patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-2411.
 
35. DeFronzo R, Hissa M, Garber A, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-1655.
 
36. Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-622.
 
37. Chacra A, Tan G, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomized controlled trial. Int J Clin Pract 2009;63:1395-1406.
 
38. Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinediones alone. J Clin Endocrinol Metab 2009;94:180-189.
 
39. Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes.Diabetes Metab Res Rev 2010;26:540-549
 
40. Drugstore.com. Accessed May 23, 2010.
 
41. Sinha A, Rajan M, Hoerger T, et al. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. Diabetes Care 2010;33:695-700.